Publications by authors named "M J Seibel"
ObjectiveThis study tests a model to improve the management of patients with an osteoporotic fracture.MethodsPatients with fractures potentially due to osteoporosis were identified from imaging reports using computerised near natural language processing. A coordinator notified the referring GP about the finding and provided follow-up to remind GPs of the need for management.
View Article and Find Full Text PDFArticle Synopsis
- * A cluster randomised controlled trial will be conducted in Sydney to test a new integrated approach for secondary fracture prevention in primary care settings, which includes alerts to doctors and management guidelines for osteoporotic fractures.
- * The primary goal of the trial is to measure how many patients get bone density scans or prescriptions for osteoporosis treatment within three months of an initial fracture diagnosis, while also tracking additional outcomes related to osteoporosis management.
A male of East Asian background in his 30s presented to the emergency department with acute onset global muscle weakness, elevated creatine kinase, profound hypokalaemia and hyperthyroidism. A diagnosis of thyrotoxic periodic paralysis was made and the myopathy resolved promptly with potassium replacement. However, 3 months after being commenced on carbimazole for hyperthyroidism, the patient developed myalgias without weakness associated with an elevated creatine kinase.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic castration-resistant prostate cancer (mCRPC) often shows loss of sensitivity to androgen receptors and activation of the PI3K/AKT/mTOR pathway, making treatment difficult due to feedback mechanisms that lead to drug resistance.
- The study suggests that gedatolisib, a potent multi-target inhibitor of the PI3K pathway and mTORC1/2, is more effective than single-node PAM inhibitors for treating prostate cancer cells, regardless of their PTEN/PIK3CA status.
- Gedatolisib's superior effectiveness arises from its ability to impact critical cell functions, and it is currently in a clinical trial combined with darolutamide for patients with mCRPC.